Structure Therapeutics Inc. (GPCR)
| Market Cap | 1.57B -0.5% |
| Revenue (ttm) | n/a |
| Net Income | -214.84M |
| EPS | -3.22 |
| Shares Out | 71.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 803,895 |
| Open | 23.00 |
| Previous Close | 22.88 |
| Day's Range | 21.77 - 23.32 |
| 52-Week Range | 20.73 - 94.90 |
| Beta | -1.37 |
| Analysts | Strong Buy |
| Price Target | 105.78 (+380.6%) |
| Est. Earnings | Nov 5, 2026 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for GPCR stock is "Strong Buy." The 12-month stock price target is $105.78, which is an increase of 380.60% from the latest price.
News
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Structure Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Aleniglipron shows up to 16% weight loss and strong safety, with phase III trials underway and key Q4 readouts expected. Oral amylin program advances with promising early data and combination strategies, while scalable manufacturing and global market expansion remain priorities.
Structure Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Aleniglipron phase III data are expected at the end of 2028, with Q4 readouts and amylin studies advancing near term. ACCG-2671 showed a six-day half-life and exploratory weight loss; cash of $1.3 billion as of June 30 is expected to fund key trials.
Structure weakness ‘disconnected’ from underlying data, says Jefferies
After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies sees the roughly 7% stock pullback following today’s dat...
Structure obesity portfolio updates ‘encouraging,’ says Clear Street
Clear Street says Structure Therapeutics (GPCR) announced “encouraging updates “across its obesity portfolio. ACCG-2671 is beginning to unlock value and aleniglipron’s 72-week open-label extension dat...
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist, and ale...
Structure Therapeutics Transcript: Study result
Revised summary: ACCG-2671, an oral amylin/calcitonin receptor agonist, showed dose-proportional PK, good safety, efficacy, and bone health benefits. Aleniglipron, an oral GLP-1 agonist, achieved 16.2% weight loss at 72 weeks with strong tolerability and cardiometabolic gains. Combination and next-gen programs are advancing with robust funding and key milestones.
Structure Therapeutics Press release: Study result
Structure Therapeutics issued a press release on September 8, 2026, disclosing material business information to investors.
Structure Therapeutics Slides: Study result
Structure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2...
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me...
Structure Therapeutics price target raised to $111 from $101 at Canaccord
Canaccord raised the firm’s price target on Structure Therapeutics (GPCR) to $111 from $101 and keeps a Buy rating on the shares. The firm said Structure reported financial results and…
Structure Therapeutics price target lowered to $97 from $100 at Citi
Citi lowered the firm’s price target on Structure Therapeutics (GPCR) to $97 from $100 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Structure Therapeutics price target lowered to $110 from $113 at Citizens
Citizens lowered the firm’s price target on Structure Therapeutics (GPCR) to $110 from $113 and keeps an Outperform rating on the shares. Structure Therapeutics continues to advance a differentiated o...
Structure Therapeutics Earnings release: Q2 2026
Structure Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Structure Therapeutics Quarterly report: Q2 2026
Structure Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Structure Therapeutics Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals passing. Strategic updates highlighted clinical progress in chronic weight management and a strong capital position to support ongoing trials.
The Next Phase Of The Obesity Drug Race
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Phar...
Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Structure Therapeutics (GPCR) to $70 from $100 and keeps a Buy rating on the shares. The firm says retatrutide’s “clean” low-dose profile…
Structure Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Recent ADA data confirmed best-in-class efficacy for oral obesity therapy, with up to 16% weight loss and rapid market adoption. Phase III will start in Q3, focusing on patient-friendly titration and long-term maintenance, while amylin and combination programs advance with robust funding.
Structure's experimental obesity pill shows no signs of liver injury
Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses of the dru...
Structure Therapeutics announces ACCESS trial data published in Nature Medicine
Structure Therapeutics (GPCR) announced a publication in Nature Medicine detailing results from the Phase 2b ACCESS clinical trial of aleniglipron for the treatment of people living with obesity and/o...
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecul...
Structure Therapeutics Slides: Corporate presentation
Structure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Structure Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Oral GLP-1 therapies are rapidly expanding the obesity market, with strong demand and high efficacy demonstrated by aleniglipron. The company is advancing both GLP-1 and Amylin programs, supported by a robust IP portfolio and $1.5B in cash, with key data and phase III trials upcoming.